Environ Toxicol Pharmacol. 2019 Oct 7;73:103271. doi: 10.1016/j.etap.2019.103271. [Epub ahead of print]

Tributyltin reduces bone mineral density by reprograming bone marrow mesenchymal stem cells in rat.

Yao W¹, Wei X², Guo H², Cheng D¹, Li H¹, Sun L³, Wang S², Guo D², Yang Y⁴, Si J⁵.

Abstract

Tributyltin (TBT), a proven endocrine disrupter, was widely used in industry and agriculture. Previous research showed that TBT could alter the balance between osteogenesis and adipogenesis, which may have significant consequences for bone health. Herein, we exposed male rats to TBT chloride (TBTCl) to evaluate the deleterious effects of TBT on bone. Exposure to 50 μg kg^-1 TBT resulted in a significant decrease in bone mineral density (BMD) at the femur diaphysis region in the rat. A dose-dependent increase in lipid accumulation and adipocyte number was observed in the bone marrow (BM) of the femur. Meanwhile, TBTCl treatment significantly enhanced the expression of PPARγ and attenuated the expression of Runx2 and β-catenin in BM. In addition, serum ALP activity of TBT-exposed rats also showed a dose-dependent decrease. These results suggest that TBT could reduce BMD via inhibition of the Wnt/β-catenin pathway and skew the adipo-osteogenic balance in the BM of rats.